secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001171843-25-002781
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos raises >$100M, posts Q1 net income $43.1M; HBV drug Phase 2 to start mid-2025
--------------------------------------------------------------------------------

- Cash grew to $137.9M after raising over $100M; expected to fund operations into H2 2026.
- Q1 2025 net income $43.1M (basic EPS $5.12); diluted net loss per share ($2.11) due to warrant fair value change.
- Phase 2 B-SUPREME study of ALG-000184 in chronic HBV expected to begin mid-2025; interim data 2026, topline 2027.
- ALG-055009 (THR-β agonist) Phase 2a HERALD showed placebo-adjusted median liver fat reduction up to 46.2%; up to 70% subjects achieved ≥30% reduction.
- ALG-097558 pan-coronavirus inhibitor has 3 clinical trials ongoing; NIAID study Q2 2025. Company seeking external funding for further development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184325002781/0001171843-25-002781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184325002781/f8k_050525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer